Abstract Number: 3246 • 2016 ACR/ARHP Annual Meeting
Predictors of Long-Term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). Predictors of short-term mortality include male sex, age>60…Abstract Number: 957 • 2016 ACR/ARHP Annual Meeting
International Patient and Physician Consensus on Psoriatic Arthritis Outcomes for Clinical Trials
Background/Purpose: A psoriatic arthritis (PsA) core domain set to be measured in randomized controlled trials (RCT) was developed by Group for Research and Assessment…Abstract Number: 972 • 2016 ACR/ARHP Annual Meeting
Outcome of the Scleroderma Population “at Risk” to Develop Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort Study
ABSTRACT: Background/Purpose: We investigated predictors of outcome, including mortality and cardiopulmonary hospitalizations in the Òat riskÓ group for pulmonary hypertension in PHAROS, a prospective longitudinal…Abstract Number: 1003 • 2016 ACR/ARHP Annual Meeting
Ultrasonography Changes during the Course of Septic Arthritis ARE Associated with Functional Outcome
Background/Purpose: The main goal of this study was to describe the US changes observed during the course of septic arthritis and their association with…Abstract Number: 70 • 2015 ACR/ARHP Annual Meeting
Data from Brazilian Fibromyalgia Patients Registry (EPIFIBRO) in 2014
Background/Purpose: –The Brazilian registry on fibromyalgia syndrome (EPIFIBRO) included 810 patients who satisfied the American College of Rheumatology Classification Criteria for Fibromyalgia (ACR1990) at the…Abstract Number: 2593 • 2015 ACR/ARHP Annual Meeting
Relationship Between Index of Activity Speed (Time Up and Go test) and Patient-Reported Outcome in Patients with Long-Standing Rheumatoid Arthritis: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function
Background/Purpose: Total management including reconstructive joint surgery and rehabilitation should be needed for further improvements of physical function for long-standing RA patients. It is very…Abstract Number: 183 • 2015 ACR/ARHP Annual Meeting
B-Mode and Power Doppler Assessment As Predictors for Short and Long-Term Clinical Outcome in Cts Patients with or without Surgical Treatment
Background/Purpose: To investigate the prognostic value of baseline B-mode and Power Doppler (PD) ultrasound assessment of the median nerve in CTS patients with or without…Abstract Number: 2915 • 2015 ACR/ARHP Annual Meeting
The Utility of Lupus Serology in Predicting Outcomes of Renal Transplantation in Lupus Patients: Systematic Review and Analysis of a Large Lupus Cohort
Background/Purpose: To study the utility of lupus serology as a predictor for kidney graft outcome in: a) a systematic review (SR) of the literature and…Abstract Number: 417 • 2015 ACR/ARHP Annual Meeting
Gender Differences in Pediatric Localized Scleroderma: Clinical and Patient-Reported Outcomes
Background/Purpose: Localized scleroderma (LS) is an autoimmune disease of the skin and underlying tissue that leads to progressive fibrosis and disability in growing children. Pediatric…Abstract Number: 2918 • 2015 ACR/ARHP Annual Meeting
Do Patients with Lupus Nephritis Who Achieve Complete Proteinuria Recovery at 2 Years Have Better Long Term Outcomes Compared to Patients with Partial Proteinuria Recovery?
Background/Purpose: The tempo of Complete Proteinuria Recovery (CPR) in Lupus Nephritis (LN) is slow and while 28% achieve CPR at year 1 this increases to…Abstract Number: 418 • 2015 ACR/ARHP Annual Meeting
Relationship of Race, Ethnicity, and Outcomes in Pediatric Localized Scleroderma: Possible Differences in Disease Activity
Background/Purpose: Pediatric localized scleroderma (LS) is an autoimmune skin and soft tissue disease that causes morbidity via progressive skin fibrosis and extracutaneous manifestations (ECMs), such…Abstract Number: 2930 • 2015 ACR/ARHP Annual Meeting
Outcome of Patients with Systemic Lupus Erythematous (SLE) after Thrombotic Events
Background/Purpose: To assess the impact of thrombotic events (TE) on 1) mortality, 2) SLE-related damage accrual; and 3) health-related quality of life (HRQoL) in patients…Abstract Number: 442 • 2015 ACR/ARHP Annual Meeting
Use of Adjunctive Neuroregulatory Medication to Improve Etanercept Treatment Response for Patients with Inflammatory Arthritis: A Pilot Study
Background/Purpose: As a proposed inflammatory biomarker for autoimmune disease1,2, the autonomic nervous system (ANS) has been assessed as a predictor of anti-TNF treatment outcome3 and…Abstract Number: 2938 • 2015 ACR/ARHP Annual Meeting
Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort
Background/Purpose: Treating to a target of remission or low disease activity state (LDAS) is an attractive potential therapeutic approach in SLE. Recently, LDAS and remission…Abstract Number: 567 • 2015 ACR/ARHP Annual Meeting
Rituximab Associated Late Onset Neutropenia – a Rheumatology Case Series and Review of the Literature
Background/Purpose: Rituximab (RTX) has been associated with late onset neutropenia (LON), defined as an absolute neutrophil count (ANC) < 1.5 x 109/L at least 4 weeks…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- Next Page »